This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
AAIC
Hybrid
2022
Symposium

Date and time:

01.08.22 at 18:00-19:00 PST

Type:

Congress:
Speakers:

Jeffrey Cummings

Professor Jeffrey Cummings

University of Nevada, Las Vegas, Nevada, US


Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

 

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

 

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), and the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010).

 

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

 

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

 

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.


Read full bio
Stephanie Monroe

Stephanie Monroe

Executive Director of African Americans Against Alzheimer’s , Washington, DC , USA


STEPHANIE J. MONROE is Director of Equity and Access and Executive Director of AfricanAmericansAgainstAlzheimer’s, a network of UsAgainstAlzheimer’s which is a national advocacy organization based in Washington, D.C. African Americans Against Alzheimer’s was founded in 2013 and is the first national network created specifically to respond to Alzheimer’s disease’s disparate impact on African Americans. By working nationally, locally, and through strategic partnerships, African Americans Against Alzheimer’s is raising awareness of the impact of Alzheimer’s health disparities on communities of color and women, the need for greater minority participation in clinical trials to find better treatments and hopefully a cure, and the importance of all communities, especially those most at risk to begin to focus on brain health and adopt risk reduction strategies that promote brain health and healthy aging.

An attorney with three decades of federal public policy experience. Stephanie is former Assistant Secretary of Education for Civil Rights. Prior to serving in that position she ended a 25-year career on Capitol Hill after holding a number of key staff positions in the United States Congress, including Chief Counsel of the U.S. Senate Committee on Health, Education, Labor and Pensions, as well as Staff Director of the Senate Subcommittee on Children and Families. With a particular emphasis of domestic policy issues involving health and education equity, Stephanie has participated in policy development and navigation of numerous policies from inception into law.


Read full bio

Welcome and introduction to the symposium and speakers

New thinking on Alzheimer’s disease diagnosis, treatment and management

Deciphering the role of the immune system in Alzheimer’s disease: current evidence and future directions

Investigating the potential role of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

Evoke and evoke+: two Phase 3 trials investigating oral semaglutide and associated biomarkers in participants with early Alzheimer’s disease

Q&A, wrap-up and learnings from the meeting and close

Related